ResoTher Pharma is pleased to announce the appointment of Samra Sanni, PhD, as Vice President, Drug Research as of today September 15th 2021. Samra will be responsible for preclinical drug research and development of novel drug molecules. Samra has a successful track record of discovering and development new peptide drugs within the cardio-metabolic space from her role as Director of Pharmacology at Bainan Biotech, and from her work with drug candidate validation and nomination at Antag Therapeutics and Novo Nordisk. Samra holds a PhD in molecular pharmacology and a MSc in human biology from University of Copenhagen, as well as a BA in medicinal chemistry from University of Århus.
We are very pleased to welcome Samra to our leadership team to lead the development of ResoTher Pharma´s pipeline of novel drugs for patients in need. Samra has significant experience from both smaller biotech and large pharma and has an impressive track record of bringing new molecules forward into clinical development.